{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9","upperLimit":"33","value":"19"},{"groupId":"OG001","lowerLimit":"18","upperLimit":"46","value":"30"}]}],"title":"Non-hematologic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19","upperLimit":"45","value":"30"},{"groupId":"OG001","lowerLimit":"33","upperLimit":"63","value":"48"}]}],"title":"Overall"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the adverse event (AE). The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE.","dispersionType":"95% Confidence Interval","groups":[{"description":"Endometrial Cancer patients receive Intensity Modulated Radiation Therapy (IMRT)","id":"OG000","title":"Endometrial Cancer: IMRT"},{"description":"Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) + Chemotherapy (cisplatin)","id":"OG001","title":"Cervical Cancer: IMRT + Chemotherapy (Cisplatin)"}],"paramType":"NUMBER","populationDescription":"Eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"From start of treatment to the end of follow-up. Maximum follow-up at time of analysis was 10.2 years for endometrium cancer patients and 9.5 years for cervical cancer patients.","title":"Percentage of Patients With Any Grade 3+ Treatment-related Adverse Events","type":"SECONDARY","unitOfMeasure":"percentage of participants"}